Have a personal or library account? Click to login
In silico selection approach to develop DNA aptamers for a stem-like cell subpopulation of non-small lung cancer adenocarcinoma cell line A549 Cover

In silico selection approach to develop DNA aptamers for a stem-like cell subpopulation of non-small lung cancer adenocarcinoma cell line A549

Open Access
|Mar 2018

References

  1. Shigdar S, Luczo J, Wei MQ, Bell R, Danks A, Liu K, et al. Aptamer therapeutics: the 21st century’s magic bullet of nanomedicine. Open Conf Proc J 2010; 1: 118-24. 10.2174/22102892010010100118
  2. Baird GS. Where are all the aptamers? Am J Clin Pathol 2010; 134: 529-31. 10.1309/AJCPFU4CG2WGJJKS
  3. Šmuc T, Ahn IY, Ulrich H. Nucleic acid aptamers as high affinity ligands in biotechnology and biosensorics. J Pharm Biomed Anal 2013; 81-82: 210-7. 10.1016/j.jpba.2013.03.014
  4. Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011; 21: 1-10. 10.1089/oli.2010.0264
  5. Ulrich H, Wrenger C. Disease-specific biomarker discovery by aptamers. Cytometry A 2009; 75: 727-33. 10.1002/cyto.a.20766
  6. Nery AA, Wrenger C, Ulrich H. Recognition of biomarkers and cell-specific molecular signatures: aptamers as capture agents. J Sep Sci 2009; 32: 1523-30. 10.1002/jssc.200800695
  7. Ni S, Yao H, Wang L, Lu J, Jiang F, Lu A, et al. Chemical modifications of nucleic acid aptamers for therapeutic purposes. Int J Mol Sci 2017; pii: E1683. 10.3390/ijms18081683.
  8. Ulrich H, Tárnok A. Flow cytometry detection of circulating tumor cells: achievements and limitations as prognostic parameters. Cytometry A 2014; 85: 201-2. 10.1002/cyto.a.22441
  9. Krebs MG, Hou J-M, Sloane R, Lancashire L, Priest L, Nonaka D, et al. Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. J Thorac Oncol [Internet]. 2012; 7: 306-15.
  10. Zhao Z, Xu L, Shi X, Tan W, Shangguan D. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst 2009; 134: 1808-14. 10.1039/B904476K
  11. Jimenez E, Sefah K, Lopez-Colon D, Van Simaeys D, Chen HWi, Tockman MS, et al. Generation of lung adenocarcinoma DNA aptamers for cancer studies. PLoS One 2012; 7: 1-7. 10.1371/journal.pone.0046222
  12. Zamay GS, Kolovskaya OS, Zamay TN, Glazyrin YE, Krat AV, Zubkova O, et al. Aptamers selected to postoperative lung adenocarcinoma detect circulating tumor cells in human blood. Mol Ther 2015; 23: 1486-96. 10.1038/mt.2015.108
  13. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One 2013; 8: e57020. 10.1371/journal.pone.0057020
  14. Yan X, Luo H, Zhou X, Zhu B, Wang Y, Bian X. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Oncol Rep 2013; 30: 2733-40. 10.3892/or.2013.2784
  15. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A.; 100: 15416-21. 10.1073/pnas.2136683100
  16. Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001; 7: 1249-53. 10.1038/nm1101-1249
  17. Telez A, Rubinstein P. Rapid method for separation of blood cells. Transfusion 1970; 10: 223-5. 10.1111/j.1537-2995.1970.tb00733
  18. Nascimento IC, Nery AA, Bassaneze V, Krieger JE, Ulrich H. Applications of aptamers in flow and imaging cytometry. Methods Mol Biol 2016; 1380: 127-34. 10.1007/978-1-4939-3197-2_10
  19. Bailey TL, Johnson J, Grant CE, Noble WS. The MEME suite. Nucleic Acids Res 2015; 43: W39-49. 10.1093/nar/gkv416
  20. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30: 2725-9. 10.1093/molbev/mst197
  21. Markham NR, Zuker M. UNAFold: Software for nucleic acid folding and hybridization. Methods Mol Biol 2008; 453: 3-31. 10.1007/978-1-60327-429-6_1
  22. Kinghorn AB, Fraser LA, Tanner JA. Aptamer bioinformatics. Int J Mol Sci 2017; pii: E2561. 10.3390/ijms18122516
  23. Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Toth IC, et al. Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J 2012; 39: 9-28. 10.1183/09031936.00190310
  24. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol 2008; 26: 983-94. 10.1200/JCO.2007.12.9858
DOI: https://doi.org/10.2478/raon-2018-0014 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 152 - 159
Submitted on: Nov 24, 2017
|
Accepted on: Feb 26, 2018
|
Published on: Mar 25, 2018
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2018 Mateja Vidic, Tina Smuc, Nika Janez, Michael Blank, Tomaz Accetto, Jan Mavri, Isis C. Nascimento, Arthur A. Nery, Henning Ulrich, Tamara T. Lah, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.